Hung Trinh: Shared Peptide Vaccine Candidates in Ovarian Cancer
Hung Trinh, Senior VP of Operations at Seneca Therapeutics, Inc., shared on LinkedIn about a recent paper by Jacopo Chiaro et al. published on NPJ:
“Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates
Epithelial ovarian cancers are largely comprised of immunogenic tumor sub-types with the degree of CD8+ T cell infiltration being prognostic of clinical outcome.
Tumor antigen-specific T cells are identified among these infiltrating T cell populations which has spurred a decade of development towards antigen-specific immunotherapies.
Despite these efforts, the success of such immunotherapies has shown to be limited. In this study, we used state-of-the art immunopeptidomics approach and a novel proteogenomic profiling method to identify potential immunogenic human leukocyte antigen class I-presented peptides from patient-derived high-grade serous ovarian cancer.
From 11 patients’ tumors, we identified promising candidates for their therapeutic potential. Of these, we selected the best 13 candidates and validated their immunogenicity in both healthy donors and cancer patients.”
Title: Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates
Authors: Jacopo Chiaro, Karita Peltonen, Kadri Õunap, Aubrey Bailey, Sara Feola, Sara Wojciechowski, Masoumeh Es-Haghi, Mikel Azkargorta, Félix Elortza, Salvatore Russo, Hanna Sallinen, Maarit Anttila, Olga Gurvich, Vincenzo Cerullo and Tuija Kekarainen
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023